Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis
In a trial comparing the JAK inhibitor upadacitinib (15 or 30 mg daily) with placebo and with the TNF-α inhibitor adalimumab, the percentage of patients with an ACR20 response at 12 weeks was 70.6% with the 15-mg dose, 78.5% with the 30-mg dose, 36.2% with placebo, and 65.0% with adalimumab. There w...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2021-04, Vol.384 (13), p.1227-1239 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1239 |
|---|---|
| container_issue | 13 |
| container_start_page | 1227 |
| container_title | The New England journal of medicine |
| container_volume | 384 |
| creator | McInnes, Iain B Anderson, Jaclyn K Magrey, Marina Merola, Joseph F Liu, Yi Kishimoto, Mitsumasa Jeka, Slawomir Pacheco-Tena, Cesar Wang, Xin Chen, Liang Zueger, Patrick Liu, John Pangan, Aileen L Behrens, Frank |
| description | In a trial comparing the JAK inhibitor upadacitinib (15 or 30 mg daily) with placebo and with the TNF-α inhibitor adalimumab, the percentage of patients with an ACR20 response at 12 weeks was 70.6% with the 15-mg dose, 78.5% with the 30-mg dose, 36.2% with placebo, and 65.0% with adalimumab. There were hepatic disorders with upadacitinib. |
| doi_str_mv | 10.1056/NEJMoa2022516 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2507711988</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2507711988</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-bb815a105e8baaafb19940a5ae60dbc5f175b437e6da8c6f35414d0bee017faa3</originalsourceid><addsrcrecordid>eNp10LtPwzAQBnALgWgpjKzIEmIM-GI7D4mlqspL5TG0c3SObZGqToqdDPz3GLUgMXDLLT99d_oIOQd2DUxmNy_zp-cOU5amErIDMgbJeSIEyw7JmLG0SERe8hE5CWHN4oAoj8mI87woGcCY3C59gxvaWbraosa66Zu2URRbTacaN40bHCpqO0_fQhdp39R06vt3H2E4JUcWN8Gc7feErO7my9lDsni9f5xNF0ktZNYnShUgMX5rCoWIVkFZCoYSTca0qqWFXCrBc5NpLOrMcilAaKaMYZBbRD4hl7vcre8-BhP6at0Nvo0nq1SyPAcoiyKqZKdq34Xgja22vnHoPytg1XdX1Z-uor_Ypw7KGf2rf8qJ4GoHnAtVa9bun6Av_0NvTg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2507711988</pqid></control><display><type>article</type><title>Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis</title><source>MEDLINE</source><source>New England Journal of Medicine Current</source><source>EZB Electronic Journals Library</source><creator>McInnes, Iain B ; Anderson, Jaclyn K ; Magrey, Marina ; Merola, Joseph F ; Liu, Yi ; Kishimoto, Mitsumasa ; Jeka, Slawomir ; Pacheco-Tena, Cesar ; Wang, Xin ; Chen, Liang ; Zueger, Patrick ; Liu, John ; Pangan, Aileen L ; Behrens, Frank</creator><creatorcontrib>McInnes, Iain B ; Anderson, Jaclyn K ; Magrey, Marina ; Merola, Joseph F ; Liu, Yi ; Kishimoto, Mitsumasa ; Jeka, Slawomir ; Pacheco-Tena, Cesar ; Wang, Xin ; Chen, Liang ; Zueger, Patrick ; Liu, John ; Pangan, Aileen L ; Behrens, Frank</creatorcontrib><description>In a trial comparing the JAK inhibitor upadacitinib (15 or 30 mg daily) with placebo and with the TNF-α inhibitor adalimumab, the percentage of patients with an ACR20 response at 12 weeks was 70.6% with the 15-mg dose, 78.5% with the 30-mg dose, 36.2% with placebo, and 65.0% with adalimumab. There were hepatic disorders with upadacitinib.</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa2022516</identifier><identifier>PMID: 33789011</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Adalimumab - adverse effects ; Adalimumab - therapeutic use ; Adult ; Adverse events ; Antirheumatic Agents - administration & dosage ; Antirheumatic Agents - adverse effects ; Antirheumatic Agents - therapeutic use ; Arthritis ; Arthritis, Psoriatic - drug therapy ; Dosage ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug dosages ; Enzyme inhibitors ; Female ; Heterocyclic Compounds, 3-Ring - administration & dosage ; Heterocyclic Compounds, 3-Ring - adverse effects ; Heterocyclic Compounds, 3-Ring - therapeutic use ; Humans ; Janus kinase ; Janus Kinase Inhibitors - therapeutic use ; Joint diseases ; Least-Squares Analysis ; Liver Diseases - etiology ; Male ; Middle Aged ; Monoclonal antibodies ; Pain ; Patients ; Placebos ; Psoriasis ; Psoriatic arthritis ; Questionnaires ; Rheumatoid arthritis ; Statistical analysis ; TNF inhibitors ; Tumor necrosis factor-α</subject><ispartof>The New England journal of medicine, 2021-04, Vol.384 (13), p.1227-1239</ispartof><rights>Copyright © 2021 Massachusetts Medical Society. All rights reserved.</rights><rights>Copyright © 2021 Massachusetts Medical Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-bb815a105e8baaafb19940a5ae60dbc5f175b437e6da8c6f35414d0bee017faa3</citedby><cites>FETCH-LOGICAL-c456t-bb815a105e8baaafb19940a5ae60dbc5f175b437e6da8c6f35414d0bee017faa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa2022516$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMoa2022516$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33789011$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>McInnes, Iain B</creatorcontrib><creatorcontrib>Anderson, Jaclyn K</creatorcontrib><creatorcontrib>Magrey, Marina</creatorcontrib><creatorcontrib>Merola, Joseph F</creatorcontrib><creatorcontrib>Liu, Yi</creatorcontrib><creatorcontrib>Kishimoto, Mitsumasa</creatorcontrib><creatorcontrib>Jeka, Slawomir</creatorcontrib><creatorcontrib>Pacheco-Tena, Cesar</creatorcontrib><creatorcontrib>Wang, Xin</creatorcontrib><creatorcontrib>Chen, Liang</creatorcontrib><creatorcontrib>Zueger, Patrick</creatorcontrib><creatorcontrib>Liu, John</creatorcontrib><creatorcontrib>Pangan, Aileen L</creatorcontrib><creatorcontrib>Behrens, Frank</creatorcontrib><title>Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>In a trial comparing the JAK inhibitor upadacitinib (15 or 30 mg daily) with placebo and with the TNF-α inhibitor adalimumab, the percentage of patients with an ACR20 response at 12 weeks was 70.6% with the 15-mg dose, 78.5% with the 30-mg dose, 36.2% with placebo, and 65.0% with adalimumab. There were hepatic disorders with upadacitinib.</description><subject>Adalimumab - adverse effects</subject><subject>Adalimumab - therapeutic use</subject><subject>Adult</subject><subject>Adverse events</subject><subject>Antirheumatic Agents - administration & dosage</subject><subject>Antirheumatic Agents - adverse effects</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis</subject><subject>Arthritis, Psoriatic - drug therapy</subject><subject>Dosage</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>Drug dosages</subject><subject>Enzyme inhibitors</subject><subject>Female</subject><subject>Heterocyclic Compounds, 3-Ring - administration & dosage</subject><subject>Heterocyclic Compounds, 3-Ring - adverse effects</subject><subject>Heterocyclic Compounds, 3-Ring - therapeutic use</subject><subject>Humans</subject><subject>Janus kinase</subject><subject>Janus Kinase Inhibitors - therapeutic use</subject><subject>Joint diseases</subject><subject>Least-Squares Analysis</subject><subject>Liver Diseases - etiology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Pain</subject><subject>Patients</subject><subject>Placebos</subject><subject>Psoriasis</subject><subject>Psoriatic arthritis</subject><subject>Questionnaires</subject><subject>Rheumatoid arthritis</subject><subject>Statistical analysis</subject><subject>TNF inhibitors</subject><subject>Tumor necrosis factor-α</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp10LtPwzAQBnALgWgpjKzIEmIM-GI7D4mlqspL5TG0c3SObZGqToqdDPz3GLUgMXDLLT99d_oIOQd2DUxmNy_zp-cOU5amErIDMgbJeSIEyw7JmLG0SERe8hE5CWHN4oAoj8mI87woGcCY3C59gxvaWbraosa66Zu2URRbTacaN40bHCpqO0_fQhdp39R06vt3H2E4JUcWN8Gc7feErO7my9lDsni9f5xNF0ktZNYnShUgMX5rCoWIVkFZCoYSTca0qqWFXCrBc5NpLOrMcilAaKaMYZBbRD4hl7vcre8-BhP6at0Nvo0nq1SyPAcoiyKqZKdq34Xgja22vnHoPytg1XdX1Z-uor_Ypw7KGf2rf8qJ4GoHnAtVa9bun6Av_0NvTg</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>McInnes, Iain B</creator><creator>Anderson, Jaclyn K</creator><creator>Magrey, Marina</creator><creator>Merola, Joseph F</creator><creator>Liu, Yi</creator><creator>Kishimoto, Mitsumasa</creator><creator>Jeka, Slawomir</creator><creator>Pacheco-Tena, Cesar</creator><creator>Wang, Xin</creator><creator>Chen, Liang</creator><creator>Zueger, Patrick</creator><creator>Liu, John</creator><creator>Pangan, Aileen L</creator><creator>Behrens, Frank</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20210401</creationdate><title>Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis</title><author>McInnes, Iain B ; Anderson, Jaclyn K ; Magrey, Marina ; Merola, Joseph F ; Liu, Yi ; Kishimoto, Mitsumasa ; Jeka, Slawomir ; Pacheco-Tena, Cesar ; Wang, Xin ; Chen, Liang ; Zueger, Patrick ; Liu, John ; Pangan, Aileen L ; Behrens, Frank</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-bb815a105e8baaafb19940a5ae60dbc5f175b437e6da8c6f35414d0bee017faa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adalimumab - adverse effects</topic><topic>Adalimumab - therapeutic use</topic><topic>Adult</topic><topic>Adverse events</topic><topic>Antirheumatic Agents - administration & dosage</topic><topic>Antirheumatic Agents - adverse effects</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis</topic><topic>Arthritis, Psoriatic - drug therapy</topic><topic>Dosage</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>Drug dosages</topic><topic>Enzyme inhibitors</topic><topic>Female</topic><topic>Heterocyclic Compounds, 3-Ring - administration & dosage</topic><topic>Heterocyclic Compounds, 3-Ring - adverse effects</topic><topic>Heterocyclic Compounds, 3-Ring - therapeutic use</topic><topic>Humans</topic><topic>Janus kinase</topic><topic>Janus Kinase Inhibitors - therapeutic use</topic><topic>Joint diseases</topic><topic>Least-Squares Analysis</topic><topic>Liver Diseases - etiology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Pain</topic><topic>Patients</topic><topic>Placebos</topic><topic>Psoriasis</topic><topic>Psoriatic arthritis</topic><topic>Questionnaires</topic><topic>Rheumatoid arthritis</topic><topic>Statistical analysis</topic><topic>TNF inhibitors</topic><topic>Tumor necrosis factor-α</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McInnes, Iain B</creatorcontrib><creatorcontrib>Anderson, Jaclyn K</creatorcontrib><creatorcontrib>Magrey, Marina</creatorcontrib><creatorcontrib>Merola, Joseph F</creatorcontrib><creatorcontrib>Liu, Yi</creatorcontrib><creatorcontrib>Kishimoto, Mitsumasa</creatorcontrib><creatorcontrib>Jeka, Slawomir</creatorcontrib><creatorcontrib>Pacheco-Tena, Cesar</creatorcontrib><creatorcontrib>Wang, Xin</creatorcontrib><creatorcontrib>Chen, Liang</creatorcontrib><creatorcontrib>Zueger, Patrick</creatorcontrib><creatorcontrib>Liu, John</creatorcontrib><creatorcontrib>Pangan, Aileen L</creatorcontrib><creatorcontrib>Behrens, Frank</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>Biological Sciences</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>ProQuest_Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McInnes, Iain B</au><au>Anderson, Jaclyn K</au><au>Magrey, Marina</au><au>Merola, Joseph F</au><au>Liu, Yi</au><au>Kishimoto, Mitsumasa</au><au>Jeka, Slawomir</au><au>Pacheco-Tena, Cesar</au><au>Wang, Xin</au><au>Chen, Liang</au><au>Zueger, Patrick</au><au>Liu, John</au><au>Pangan, Aileen L</au><au>Behrens, Frank</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2021-04-01</date><risdate>2021</risdate><volume>384</volume><issue>13</issue><spage>1227</spage><epage>1239</epage><pages>1227-1239</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>In a trial comparing the JAK inhibitor upadacitinib (15 or 30 mg daily) with placebo and with the TNF-α inhibitor adalimumab, the percentage of patients with an ACR20 response at 12 weeks was 70.6% with the 15-mg dose, 78.5% with the 30-mg dose, 36.2% with placebo, and 65.0% with adalimumab. There were hepatic disorders with upadacitinib.</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>33789011</pmid><doi>10.1056/NEJMoa2022516</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2021-04, Vol.384 (13), p.1227-1239 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_journals_2507711988 |
| source | MEDLINE; New England Journal of Medicine Current; EZB Electronic Journals Library |
| subjects | Adalimumab - adverse effects Adalimumab - therapeutic use Adult Adverse events Antirheumatic Agents - administration & dosage Antirheumatic Agents - adverse effects Antirheumatic Agents - therapeutic use Arthritis Arthritis, Psoriatic - drug therapy Dosage Dose-Response Relationship, Drug Double-Blind Method Drug dosages Enzyme inhibitors Female Heterocyclic Compounds, 3-Ring - administration & dosage Heterocyclic Compounds, 3-Ring - adverse effects Heterocyclic Compounds, 3-Ring - therapeutic use Humans Janus kinase Janus Kinase Inhibitors - therapeutic use Joint diseases Least-Squares Analysis Liver Diseases - etiology Male Middle Aged Monoclonal antibodies Pain Patients Placebos Psoriasis Psoriatic arthritis Questionnaires Rheumatoid arthritis Statistical analysis TNF inhibitors Tumor necrosis factor-α |
| title | Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T15%3A15%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Trial%20of%20Upadacitinib%20and%20Adalimumab%20for%20Psoriatic%20Arthritis&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=McInnes,%20Iain%20B&rft.date=2021-04-01&rft.volume=384&rft.issue=13&rft.spage=1227&rft.epage=1239&rft.pages=1227-1239&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMoa2022516&rft_dat=%3Cproquest_cross%3E2507711988%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2507711988&rft_id=info:pmid/33789011&rfr_iscdi=true |